Happy New Year!
Great inquiry regarding transplant pts & the use of ICI’s. Our practice has a handful of transplant pts, we have tended to shy away from pd-1 inhibitiors due to some case studies of organ transplant rejection. Pts have in these cases been treated with a CTLA-4 inhibitor. However, some of the more recent case studies have a mix of pts receiving pd-1 or combination therapies and tolerating these therapies without rejection. We have not yet had a pt with met SCC related to immune suppression secondary to transplant, we have only treated standard of care pts with cemiplimab. More case studies and discussion are certainly needed to compile more risk vs benefit info.